A number of other brokerages have also recently issued reports on PDSB. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, October 11th. B. Riley restated a “buy” rating on shares of PDS Biotechnology in a report on Friday, October 6th. Finally, Oppenheimer decreased their price target on PDS Biotechnology from $23.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, November 15th.
PDS Biotechnology Trading Up 0.3 %
Hedge Funds Weigh In On PDS Biotechnology
Institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. acquired a new position in shares of PDS Biotechnology in the 4th quarter valued at approximately $45,000. Strs Ohio acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $29,000. Allspring Global Investments Holdings LLC acquired a new position in shares of PDS Biotechnology in the 3rd quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC raised its position in shares of PDS Biotechnology by 187.7% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 6,131 shares of the company’s stock valued at $31,000 after purchasing an additional 4,000 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $37,000. 25.78% of the stock is owned by institutional investors and hedge funds.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
- Five stocks we like better than PDS Biotechnology
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- The most upgraded stocks in November have two things in common
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Monday.com rocked earnings like it’s the weekend
- With Risk Tolerance, One Size Does Not Fit All
- Plan to own one retailer? Make it this one
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.